Has brigatinib/brigatinib been successfully marketed in China?
Brigatinib/The original drug Brigatinib (Brigatinib) has been approved for marketing in China and has been included in the Class B reimbursement directory, providing a highly accessible oral targeted therapy option for patients with ALK fusion-positive non-small cell lung cancer. This drug effectively inhibits ALK signaling by irreversibly binding to ALK kinase, thereby blocking the proliferation and survival of tumor cells. It is an important representative of second-generation ALK inhibitors in clinical practice.

In the Chinese market, brigatinib has various specifications, mainly including30mg 14 tablets, 90mg 7 tablets, 90mg 7 tablets 4 boards, and 180mg 7 tablets 4 boards and other different packaging. These specifications are designed to provide patients with personalized dose adjustment and treatment convenience. Small doses can be used for tolerance assessment in the initial stage, and then adjusted to maintenance doses based on efficacy and safety to ensure the feasibility of long-term treatment.
After being included in medical insurance, the economic accessibility of brigatinib has been significantly improved. When patients purchase through medical insurance channels in the hospital, they can enjoy a certain percentage of reimbursement, thus reducing their financial burden. Especially for patients on long-term maintenance treatment, medical insurance coverage has significantly reduced monthly medication costs, making continued medication and long-term management possible.
In addition, the brigatinib marketed in China has the same ingredients as the overseas original drug, and maintains unified standards in terms of clinical efficacy and safety. When using it, doctors can choose the appropriate dosage and packaging combination according to the patient's individual conditions. At the same time, combined with regular review and laboratory monitoring, they can evaluate the efficacy and adjust the medication plan. The domestic launch not only improves the convenience for patients to obtain the drug, but also provides a solid foundation for the standardized treatment of ALK fusion non-small cell lung cancer.
Overall, brigatinib has been successfully launched in China and its accessibility has been improved through medical insurance inclusion. The diverse specifications and packaging designs on the market, combined with doctors' individualized treatment plans, enable patients to achieve safe, effective and long-term ALK targeted therapy.
Reference materials:https://www.alunbrig.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)